Respiratory drugmaker Beyond Air Q2 net loss misses estimates

Reuters11-11
Respiratory drugmaker <a href="https://laohu8.com/S/XAIR">Beyond Air</a> <a href="https://laohu8.com/S/QTWO">Q2</a> net loss misses estimates

Overview

  • Beyond Air fiscal Q2 revenue rises 128% YoY to $1.8 mln, driven by LungFit PH demand

  • Net loss and operating loss for Q2 missed analyst expectations

  • Company updates fiscal 2026 revenue guidance to $8-$10 mln

Outlook

  • Beyond Air updates fiscal 2026 revenue guidance to $8-10 mln

  • Company anticipates FDA approval of second-gen LungFit PH by end of 2026

  • Recent capital infusion to support commercial and regulatory initiatives

Result Drivers

  • LUNGFIT PH DEMAND - Revenue growth driven by increased demand for LungFit PH in the U.S.

  • GLOBAL EXPANSION - International revenue growth supported by new distribution agreements in multiple countries

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 EPS

-$1.25

Q2 Net Income

Miss

-$8.26 mln

-$6.80 mln (4 Analysts)

Q2 Operating Income

Miss

-$7.66 mln

-$7 mln (4 Analysts)

Q2 Gross Profit

-$298,000

Q2 Operating Expenses

-$7.36 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for Beyond Air Inc is $11.50, about 84.7% above its November 7 closing price of $1.76

Press Release: ID:nGNXbLsGh7

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment